3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
72
Breast Neoplasms
9
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
6
Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Prostate Cancer Metastatic
3
Metastatic Castration Resistant Prostate Cancer
3
Bulbo-Spinal Atrophy, X-Linked
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Metastatic Hormone Sensitive Prostate Cancer
2
Melanoma
2
mCRPC
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ureteral Diseases
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Seizures
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Pancreatic Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Squamous Cell
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Interventions
blinatumomab
4
Rituximab
4
Cyclophosphamide
3
ponatinib
2
Vorinostat
2
Vincristine
2
Prednisone
2
Ifosfamide
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
Bortezomib
2
tetulomab tetraxetan lu-177
1
pembrolizumab
1
pegaspargase
1
ibrutinib
1
ibritumomab tiuxetan
1
durvalumab
1
cobomarsen
1
asparaginase erwinia chrysanthemi recombinant
1
acalabrutinib
1
Methotrexate
1
Melphalan
1
Lutetium
1
Lenalidomide
1
KW-2478
1
Imatinib Mesylate
1
Hsp90 inhibitor KU757
1
Dexamethasone
1
Daunorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Immunoproliferative Disorders
×
enzalutamide
×
Clear all
No trials found.